SuperGen Reports 2007 Third Quarter Financi...(in a Phase I clinical trial of MP470 a ....),Health

novel, oral, multi-targeted tyrosine kinase inhibitor (TKI). The

study is also open to accrual at South Texas Accelerated Research

Therapeutics (START) in San Antonio, Texas. The trial is expected to

enroll up to 30 patients at the two study centers. The Phase I trial

is an accelerated titration dose-escalation study designed to assess

the safety and tolerability of MP470, and to determine the maximum

tolerated dose of the compound in patients with advanced-stage solid

tumors. Additionally, the Company will assess pharmacokinetic and

biomarker data from the study to assist in designing follow-on

clinical studies for the use of MP470 as a single agent and in

combination treatment modalities.

August 2007:

-- The Company announced the retirement of Audrey F. Jakubowski, Ph.D.,

Chief Regulatory and Quality Officer. Dr. Jakubowski's primary

responsibilities were transitioned to David S. Smith, Ph.D., who

joined SuperGen in March 2007 as Vice President, Regulatory and

Quality Affairs. Most recently, Dr. Smith was Senior Director,

Regulatory Strategy at Wyeth Consumer Healthcare.

Conference Call Information

SuperGen will host a conference call to discuss the results of the 2007 third quarter today at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast of the conference call is accessible via the investor relations section of the Company's Web site at http://ir.supergen.com. A webcast replay of the conference call will be available for 90 days.

About SuperGen

Based in Dublin, Calif., SuperGen Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a
'/>"/>